Skip to content

Several new candidates in HIV drug pipeline discussed at conference

Kirsten White at CROI 2017. Photo by Liz Highleyman, hivandhepatitis.com

Studies look at brain and cognitive changes in people with HIV as they age

Early adherence to ART key to long-term virological outcomes

'Test and treat' study shows second phase is finding more people with HIV and getting them onto treatment

Glecaprevir/pibrentasvir for hepatitis C can be safely administered with common antiretrovirals

Dolutegravir monotherapy fails to maintain HIV viral suppression, but dolutegravir + lamivudine looks good

DAA therapy cures most people with HIV/HCV co-infection with decompensated cirrhosis or liver transplants

D:A:D study – long-term use of darunavir/ritonavir modestly increases the risk of cardiovascular disease

Simple risk score can identify gay men who may have acute HIV infection